Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia
| Autor: | A Christofides, M Shafey, S Doucette, S Dolan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Canada Chronic lymphocytic leukemia medicine.disease_cause Medical Oncology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Pandemic Antineoplastic Combined Chemotherapy Protocols medicine Humans 030212 general & internal medicine Protein Kinase Inhibitors Societies Medical Coronavirus Clinical Oncology Clinical Trials as Topic Venetoclax business.industry Refractory CLL treatment-naïve disease Congresses as Topic medicine.disease Leukemia Lymphocytic Chronic B-Cell relapsed disease refractory disease Treatment Outcome chemistry 030220 oncology & carcinogenesis Ibrutinib untreated disease Acalabrutinib business |
| Zdroj: | Current Oncology Volume 27 Issue 4 Pages 7009-432 |
| ISSN: | 1718-7729 |
| Popis: | Because of the global coronavirus pandemic, the 2020 annual scientific meeting of the American Society of Clinical Oncology took place virtually, 29&ndash 30 May. At the meeting, results from key studies about the treatment of chronic lymphocytic leukemia (cll) were disseminated. Studies examined the efficacy and safety of ibrutinib, acalabrutinib, zanubrutinib, and venetoclax as monotherapy or in combination with novel agents for patients with treatment-naï ve and relapsed or refractory cll. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about potential effects on Canadian practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|